Affiliations 

  • 1 FAFP, FRACGP, Department of Family Medicine, IMU University, Clinical Campus, Jalan Rasah, Bukit Rasah, Seremban, Negeri Sembilan, Malaysia. Email: SasikalaDevi@imu.edu.my
  • 2 MCGP, FRCOG, Department of Obstetrics and Gynaecology, IMU University, Clinical Campus, Jalan Rasah, Bukit Rasah, Seremban, Negeri Sembilan, Malaysia
PMID: 39780915 DOI: 10.51866/rv.620

Abstract

Vulvodynia manifests as persistent vulvar pain, affecting both sexual well-being and overall quality of life. While the precise cause remains elusive, various multifaceted predisposing and precipitating factors have been identified. Neurobiological and psychosocial elements contribute to a better understanding of the management of this complex disorder. Initial evaluation with detailed history-taking and focused pelvic examination are essential to exclude organic diseases contributing to vulvar pain. Management strategies are based on clinical experience, including non-pharmacological approaches and cognitive behavioural therapy. Oral pain-blocking medications such as serotonin-norepinephrine reuptake inhibitors and gabapentin as well as topical treatments such as oestrogen, lidocaine and gabapentin may be considered. More robust evidence is required for pharmacological treatments. Referral to a multidisciplinary team may be required in a proportion of patients who do not respond to conventional treatment. This concise review highlights the contemporary understanding of vulvodynia and proposes a practical approach within primary care settings.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.